InvestLog
ADIL Adial Pharmaceuticals, Inc. logo

ADIL Adial Pharmaceuticals, Inc.

Healthcare
$2.08-9.57%ClosedMarket Cap: $2.0M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.77

P/S

0.00

EV/EBITDA

0.34

DCF Value

$7.96

FCF Yield

-326.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-162.8%

ROA

-148.7%

ROIC

-202.7%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-2.0M$—
Q4 null$0.00$-2.0M$—
FY null$0.00$-8.0M$—
Q3 null$0.00$-1.8M$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$8.00

Target (Median)

$8.00

Target Range

$8.00 - $8.00

1 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell
Maxim GroupBuy
2025-09-30

Trading Activity

Insider Trades

View All
Shah Vinayofficer: Chief Financial Officer
SellThu Apr 09
Schuyler Kevindirector
SellThu Apr 09
Goodman Tonydirector, officer: Chief Operating Officer
SellThu Apr 09
Gilliland Robertson H.director
SellThu Apr 09
Claiborne Cary Jdirector, officer: Chief Executive Officer
SellThu Apr 09

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

—

Beta

1.27

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Peers

ACXP logoACXPAPRE logoAPREBCDA logoBCDABCLI logoBCLICDIO logoCDIOCELZ logoCELZHCWB logoHCWBKPRX logoKPRXMTNB logoMTNBNRSN logoNRSN